Metachronous Cancer in the Stomach Remnant

[1] Nozaki I(2010)Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery World J Surg 34 1548-1554

[2] Nasu J(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697

[3] Kubo Y(2010)Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment Expert Rev Mol Diagn 10 541-545

[4] Tanada M(2010)Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11 283-287

[5] Nishimura R(2009)Current concerns and challenges towards tailored anti-angiogenic therapy in cancer Expert Rev Anticancer Ther 9 1413-1446

[6] Kurita A(2009)Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology Ann Surg 249 1067-1068

[7] Bang YJ(2009)Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice Ann Surg Oncol 16 1771-1782

[8] Cutsem E(2010)Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance Ann Surg Oncol 17 14-17

[9] Feyereislova A(2010)Complete genome sequencing and network modeling to overcome trastuzumab resistance Pharmacogenomics 11 1039-1043

[10] Roukos DH(2010)From tumor size and HER2 status to systems oncology for very early breast cancer treatment Expert Rev Anticancer Ther 10 123-128

[1] Nozaki I(2010)Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery World J Surg 34 1548-1554

[2] Nasu J(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697

[3] Kubo Y(2010)Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment Expert Rev Mol Diagn 10 541-545

[4] Tanada M(2010)Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11 283-287

[5] Nishimura R(2009)Current concerns and challenges towards tailored anti-angiogenic therapy in cancer Expert Rev Anticancer Ther 9 1413-1446

[6] Kurita A(2009)Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology Ann Surg 249 1067-1068

[7] Bang YJ(2009)Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice Ann Surg Oncol 16 1771-1782

[8] Cutsem E(2010)Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance Ann Surg Oncol 17 14-17

[9] Feyereislova A(2010)Complete genome sequencing and network modeling to overcome trastuzumab resistance Pharmacogenomics 11 1039-1043

[10] Roukos DH(2010)From tumor size and HER2 status to systems oncology for very early breast cancer treatment Expert Rev Anticancer Ther 10 123-128